Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. Alexandria J. Med. 50: 203-209.Bader T, Ismail A: Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: propensity for lung metastasis. Alexandria J Med 2014;50:203-...
3.2.3 非小细胞肺癌肺癌是一种常见的恶性肿瘤,可分为非小细胞肺癌(non-small cell lung cancer,NSCLC) 和小细胞肺癌(small cell lung cancer,SCLC), 其中 NSCLC 占肺癌的 80% ~ 85%[71]。尽管近年对肺癌免疫治疗及靶向药物的研究取得一定进展,但...
https://www.cancer.org/cancer/colon-rectal-cancer/treating/targeted-therapy.html [3]FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation | FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combi...
目前猜测，这种耐药性和KRAS基因二次突变密切相关，也有部分证据表明，耐药性和RTK-RAS信号通路被激活密切...
Pembrolizumab gained accelerated approval from the FDA in May 2017 for unresectable or metastatic colon cancer that has tested positive for microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) and has progressed following treatment with a fluoropyrimidine, oxaliplatin, and ...
Kopetz noted that the combination now is recommended by the National Comprehensive Cancer Network guidelines, and that Phase III trials are currently ongoing. NewsAnti cancer drugsColon cancerColorectal cancerMonoclonal antibodiesMutationNon-small cell lung cancerPhase I clinical trials (Clinical trial)...
3月27日,第33轮长征疑难肿瘤分子肿瘤专家委员会(Molecular Tumor board,MTB)在长征医院如期举行。MTB是一种多学科协作的模式,整合多样化的患者信息,从分子层面讨论晚期肿瘤患者的治疗问题。长征医院MTB会议由海军军医大学附属长征医院肿瘤科臧远胜主任...
- 《Clinical Cancer Research》 被引量: 393发表: 2012年 KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009; 15(23):7322-...
However, the role of KRAS as a predictive marker has not been demonstrated for less advanced disease: recently published findings from a phase III randomized trial of patients with stage III colon cancer indicated no benefit in 3-year disease-free survival with the addition of cetuximab to ...
MK2206, an AKT inhibitor, was found to improve the pathological complete remission (CR) rate in patients with breast cancer associated with positive hormone receptors [80]. Uprosertib (GSK795) is an ATP-competitive AKT inhibitor, which is evaluated in a phase I study involving patients with ...